Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $93 from $74 and keeps an Overweight rating on the shares. Consistent with the firm’s longitudinal channel checks, Ohtuvayre’s launch continues to build momentum with more prescriptions in the first two months of Q1 2025 than in Q4 2024, marking another quarter in which Ohtuvayre is tracking well above comparable sales/Street.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: